Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
bio
9
×
crispr
9
×
tc
biology
jennifer doudna
biotechnology
editas medicine
enzymes
genetics
health
non-coding rna
repetitive dna sequences
american biochemists
berkeley college of chemistry faculty
biotech
crispr therapeutics
crystallographers
drama
emerging technologies
harvard university alumni
howard hughes medical investigators
living people
medicine
members of the united states national academy of sciences
molecular biology
university of california
yale department of molecular biophysics & biochemistry faculty
1963 births
2025
ad-comm
affimed
akcea therapeutics
allogene therapeutics
american women scientists
amicus therapeutics
antibiotic resistance
antimicrobial
applied genetics
approval
apremilast
What
crispr
technology
cas
editing
gene
read
biotech
doudna
jennifer
patent
using
antibiotic
berkeley
berkeley’s
called
centers
chemistry
industry
institute
inventor
million
molecular
nearly
rights
scientists
shares
snip
think
use
year
according
acts
actually
aids
allogene
allowing
anti
antibiotics
argument
arguments
Language
Current search:
bio
×
crispr
×
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@techcrunch.com
5 years ago
HP is ‘printing’ drugs for the CDC to speed up antibiotic testing
@techcrunch.com
6 years ago
Scientists have eliminated HIV in mice using CRISPR
@techcrunch.com
7 years ago
CRISPR-Cas9 inventor Jennifer Doudna’s plans on moving forward, genetically modifying humans
@techcrunch.com
7 years ago
Move over Cas9, CRISPR-Cas3 might hold the key to solving the antibiotics crisis
@techcrunch.com
7 years ago
Oral arguments for who owns CRISPR-Cas9 starts next month
@techcrunch.com
7 years ago
CRISPR loses Nobel to tiny machines
@techcrunch.com
7 years ago
Jennifer Doudna, inventor of gene editing technology CRISPR Cas9, is coming to Disrupt
@techcrunch.com
8 years ago
Editas biotech stock drops by 26% over CRISPR patent dispute